Horizon Pharma to pay $800M for rare disease drug developer

Horizon Pharma will spend about $800 million to buy Raptor Pharmaceutical and expand its portfolio of rare disease treatments, a growing area of focus for drugmakers.

The Ireland-based drug developer said Monday that the deal will strengthen its business in the United States and provide a platform to expand in Europe and other international markets.

Raptor's portfolio includes Procysbi, which treats a rare metabolic disorder, and Quinsair, approved for managing a chronic pulmonary infection in adult patients with cystic fibrosis.

Horizon Pharma Plc. will pay $9 in cash for each share of Novato, California-based Raptor Pharmaceutical Corp. and expects to close the deal in the fourth quarter.

Drugmakers in recent years have been shifting more money to developing rare disease treatments, as mass-market drugs lose patent protections.

New York-traded shares of Horizon Pharma rose $1.33, or 7.7 percent, to $18.59 in afternoon trading. Shares of Raptor Pharmaceutical jumped $1.51, or 20.2 percent, to $8.96.

This story has been automatically published from the Associated Press wire which uses US spellings

Get the news delivered straight to your inbox

Receive the day’s news, sport and entertainment in our daily email newsletter


© Copyright 2016, NZME. Publishing Limited

Assembled by: (static) on production bpcf04 at 26 Oct 2016 12:45:27 Processing Time: 435ms